| Wenyi Luo, MD | |
|
333 Cedar St, New Haven, CT 06510-3206 | |
| (203) 432-4771 | |
| Not Available |
| Full Name | Wenyi Luo |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 23 Years |
| Location | 333 Cedar St, New Haven, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457795270 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Bridgeport Hospital | Bridgeport, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yale University | 9436061736 | 2241 |
News Archive
Scientists at the University of Exeter have identified a way to "rescue" cells that have genetically mutated, paving the way to a possible new treatment for rare terminal childhood illness such as mitochondrial disease.
In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.
Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.
Researchers from University Medical Centre Utrecht have been investigating the efficiency of vaccines against the alpha variant in the Netherlands.
› Verified 9 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
Scientists at the University of Exeter have identified a way to "rescue" cells that have genetically mutated, paving the way to a possible new treatment for rare terminal childhood illness such as mitochondrial disease.
In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.
Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.
Researchers from University Medical Centre Utrecht have been investigating the efficiency of vaccines against the alpha variant in the Netherlands.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wenyi Luo, MD 333 Cedar St, New Haven, CT 06510-3206 Ph: () - | Wenyi Luo, MD 333 Cedar St, New Haven, CT 06510-3206 Ph: (203) 432-4771 |
News Archive
Scientists at the University of Exeter have identified a way to "rescue" cells that have genetically mutated, paving the way to a possible new treatment for rare terminal childhood illness such as mitochondrial disease.
In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.
Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.
Researchers from University Medical Centre Utrecht have been investigating the efficiency of vaccines against the alpha variant in the Netherlands.
› Verified 9 days ago
Dr. Barton Charles Kenney, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 20 York Street, T-209, Yale-new Haven Hospital, New Haven, CT 06510 Phone: 203-688-2259 Fax: 203-688-5599 | |
Edward S Lee, MD, PHD Pathology Medicare: Not Enrolled in Medicare Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Melissa Anne Much, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 20 York St # T-209, Yale-new Haven Hospital, New Haven, CT 06510 Phone: 203-688-2259 Fax: 203-688-5599 | |
Haris Mirza, MD Pathology Medicare: Medicare Enrolled Practice Location: Yale School Of Medicine, Dept. Of Pathology, 20 York St, New Haven, CT 06510 Phone: 877-925-3522 Fax: 203-737-5388 | |
Raffaella Morotti, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 310 Cedar St, Pathology Department, New Haven, CT 06510 Phone: 203-737-6325 | |
Dr. Richard Rodion Rathbone, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 20 York St, Yale-new Haven Hospital, New Haven, CT 06504 Phone: 203-688-2439 Fax: 203-688-5103 | |
Dr. Mahboubeh Rahmani, MD Pathology Medicare: Medicare Enrolled Practice Location: 310 Cedar St, New Haven, CT 06510 Phone: 203-737-2115 |